Trial Profile

Open-label Phase 2 Study of Single-agent Erlotinib for Patients With Pediatric Ependymoma Previously Treated With Oral Etoposide in Protocol OSI-774-205

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 14 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary) ; Etoposide
Indications Ependymoma
Focus Adverse reactions; Therapeutic Use
Acronyms PETEY
Sponsors OSI Pharmaceuticals

Most Recent Events

12 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
12 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
04 Apr 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov. (Parent trial: NCT01032070).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com